Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer

NCT05104567 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05104567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05104567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
December 9, 2021
Completion date
September 9, 2024
Enrollment
138 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastric cancer, hepatocellular carcinoma, oesophageal adenocarcinoma, oesophageal squamous cell carcinoma